Salarius Pharmaceuticals Inc (SLRX)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

2450 HOLCOMBE BLVD HOUSTON, TX 77021

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options. Salarius' lead candidate, seclidemstat, is being studied as a potential treatment for pediatric cancers, solid tumors and other cancers with limited treatment options. Seclidemstat is currently in a Phase 1/2 clinical trial for relapsed/refractory Ewing sarcoma and Ewing-related sarcomas, also called FET-translocated sarcomas. Ewing sarcoma has received Fast Track Designation, Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Food and Drug Administration. Salarius is also developing seclidemstat for several cancers with high unmet medical need, with a second Phase 1/2 clinical study in advanced solid tumors, including prostate, breast, and ovarian cancers. Salarius has received financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and was also a recipient of a Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT).

Data as of 2021-07-25 17:18:22 -0400
Market Cap38.661 Million Shares Outstanding44.773 Million Avg 30-day Volume784.851 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS0
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE0.18 Enterprise Value
Total Cash Current Debt Gross Profit
BETA1.44968 52-week High/Low3.5 / 0.632 Next Earnings Date2021-08-11 Price to Cash FLow (P/CF) -9999999.0
Data provided by IEX Cloud

Are you looking for this stock instead?

View SEC Filings from SLRX instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 0 0 (0.0%) 0 (0.0%)
Funds Holding: 35 26 34.62% 14 (0.82%) 9 (0.52%) 55.56%
13F shares: 15.481 Million 4.263 Million 263.13% 8.554 Million 2.344 Million 264.93%
% Ownership 34.6067 21.4837 61.08% 19.1223 11.8128 61.88%
New Positions: 15 8 87.5% 6 2 200.0%
Increased Positions 13 5 160.0% 7 2 250.0%
Closed Positions 5 1 400.0% 1 1 0.0%
Reduced Positions 1 3 -66.67% 1
Total Calls
Total Puts
PUT/CALL Ratio
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding SLRX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding SLRX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

ARTHUR DAVID J. CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
96,247 2021-05-03 4

ROSENBLUM MARK J EXEC VP FINANCE, CFO

  • Officer
26,286 2021-05-03 4

MCVICAR WILLIAM K.

  • Director
0 2020-12-02 1

MCCREEDY BRUCE J JR.

  • Director
0 2020-12-02 1

LAMMERS PAUL

  • Director
0 2020-12-02 1

HANISH ARNOLD C

  • Director
0 2020-12-02 2

BURLESON TESS

  • Director
0 2020-12-02 1

LIEBER JONATHAN I

  • Director
0 2020-12-02 1

NORTHRUP JONATHAN P

  • Director
0 2020-03-23 0

JORDAN SCOTT CHIEF BUSINESS OFFICER

  • Officer
31,609 2020-02-18 0

CHUANG PAO-YU CONTROLLER

  • Officer
0 2019-09-10 0

BOSTON FOUNDATION, INC.

  • 10% Owner
No longer subject to file 2019-01-09 0

WESTPHAL CHRISTOPH H

  • 10% Owner
3,941,118 2018-10-16 0

LONGWOOD FUND II, L.P.

  • 10% Owner
No longer subject to file 2018-10-16 0

HUTT PETER BARTON

  • Director
0 2018-07-25 0

KOZIN MARC D

  • Director
0 2018-07-25 0

RANDLE STUART A

  • Director
0 2018-07-25 0

STACY MICHELLE

  • Director
0 2018-07-25 0

TUNG ROGER D

  • Director
0 2018-07-25 0

MCCABE JOHN P. CHIEF FINANCIAL OFFICER

  • Officer
0 2018-06-14 0

WESSEL THOMAS CHIEF MEDICAL OFFICER

  • Officer
0 2018-01-17 0

WOO ELIZABETH SVP, INVESTOR RELATIONS

  • Officer
0 2018-01-17 0

MACKINNON RODERICK

  • Director
0 2017-07-26 0

CAPELLO JEFFREY D

  • Director
0 2017-07-26 0

PEREZ ROBERT J

  • Director
0 2017-07-26 0

HADFIELD ROBERT GENERAL COUNSEL & SECRETARY

  • Officer
0 2017-01-18 0

LINDEMANN KATHARINE CHIEF OPERATING OFFICER

  • Officer
0 2017-01-18 0

SCULLEY JOHN

  • Director
0 2016-06-08 0

HAHN MARINA PRESIDENT, CONSUMER

  • Officer
0 2015-11-11 0

CERMAK JENNIFER VP PROGRAM MANAGEMENT

  • Officer
0 2015-01-28 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
SALARIUS PHARMACEUTICALS INC SLRX 2021-07-28 17:45:03 UTC -4.8614 4.9414 550000
SALARIUS PHARMACEUTICALS INC SLRX 2021-07-28 17:15:03 UTC -4.8614 4.9414 550000
SALARIUS PHARMACEUTICALS INC SLRX 2021-07-28 16:45:03 UTC -4.8614 4.9414 550000
SALARIUS PHARMACEUTICALS INC SLRX 2021-07-28 16:15:02 UTC -4.8614 4.9414 550000
SALARIUS PHARMACEUTICALS INC SLRX 2021-07-28 15:45:03 UTC -4.8614 4.9414 550000
SALARIUS PHARMACEUTICALS INC SLRX 2021-07-28 15:15:03 UTC -4.8614 4.9414 550000
SALARIUS PHARMACEUTICALS INC SLRX 2021-07-28 14:45:02 UTC -4.2409 4.3209 550000
SALARIUS PHARMACEUTICALS INC SLRX 2021-07-28 14:15:03 UTC -4.2409 4.3209 300000
SALARIUS PHARMACEUTICALS INC SLRX 2021-07-28 13:45:02 UTC -4.2409 4.3209 300000
SALARIUS PHARMACEUTICALS INC SLRX 2021-07-28 13:15:03 UTC -4.2409 4.3209 300000
SALARIUS PHARMACEUTICALS INC SLRX 2021-07-28 12:45:03 UTC -4.2409 4.3209 300000
SALARIUS PHARMACEUTICALS INC SLRX 2021-07-27 22:15:03 UTC -4.2409 4.3209 250000
SALARIUS PHARMACEUTICALS INC SLRX 2021-07-27 21:45:03 UTC -4.2326 4.3126 250000
SALARIUS PHARMACEUTICALS INC SLRX 2021-07-27 21:15:03 UTC -4.2326 4.3126 250000
SALARIUS PHARMACEUTICALS INC SLRX 2021-07-27 20:45:03 UTC -4.2262 4.3062 250000
SALARIUS PHARMACEUTICALS INC SLRX 2021-07-27 20:15:03 UTC -4.2262 4.3062 250000
SALARIUS PHARMACEUTICALS INC SLRX 2021-07-27 19:45:02 UTC -4.2262 4.3062 250000
SALARIUS PHARMACEUTICALS INC SLRX 2021-07-27 19:15:02 UTC -4.2262 4.3062 250000
SALARIUS PHARMACEUTICALS INC SLRX 2021-07-27 18:45:03 UTC -4.2262 4.3062 250000
SALARIUS PHARMACEUTICALS INC SLRX 2021-07-27 18:15:02 UTC -4.2262 4.3062 250000

Current Active Short Positions

Get more info on our International short position coverage here

Holder Issuer Net Short Position Position Date Origin
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund SLRX -5400.0 shares, $-7992.0 2021-03-31 N-PORT

Short Position History (International Only)

Holder Net Short Position Position Date Origin
Squarepoint Ops LLC Salarius Pharmaceuticals Inc 0.54% 2019-10-09 UK
Squarepoint Ops LLC Salarius Pharmaceuticals Inc 0.61% 2019-10-10 UK
Squarepoint Ops LLC Salarius Pharmaceuticals Inc 0.7% 2019-01-01 GERMANY
Squarepoint Ops LLC Salarius Pharmaceuticals Inc 0.64% 2019-11-13 GERMANY

Elevate your investments